Search
Syncromune's AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC
CEO Eamonn Hobbs describes the responses Syncromune is seeing in an early phase 1 prostate cancer study.
Apr 8, 2024
top of page
Search
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
​
​Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
bottom of page